Table 2.
Most frequent toxicities in the PALOMA-3 phase III trial (n = 517) [5]
| Palbociclib + Fulvestrant ( n = 345) | Placebo + Fulvestrant ( n = 172) | |||||
|---|---|---|---|---|---|---|
| All in % | Grade 3 in % | Grade 4 in% | All in % | Grade 3 in % | Grade 4 in % | |
| Neutropenia | 79 | 53 | 9 | 4 | – | <1 |
| Leukopenia | 46 | 25 | <1 | 4 | – | <1 |
| Anemia | 26 | 3 | – | 10 | 2 | – |
| Thrombocytopenia | 19 | 2 | <1 | – | – | – |
| Fatigue | 38 | 2 | – | 27 | 1 | – |
| Nausea | 29 | – | – | 26 | <1 | – |
| Headache | 21 | <1 | – | 17 | – | – |
| Upper respiratory infection | 19 | <1 | – | 16 | – | – |
| Diarrhea | 19 | – | – | 17 | <1 | – |
| Constipation | 17 | – | – | 14 | – | – |
| Alopecia | 15 | – | – | 6 | – | – |